The latest Investing Matters Podcast episode with Inclusive Asset Management's Alexandra McGuigan has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 51.00
Bid: 50.50
Ask: 51.50
Change: -0.50 (-0.97%)
Spread: 1.00 (1.98%)
Open: 51.50
High: 51.70
Low: 51.00
Prev. Close: 51.50
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EXECUTIVE CHANGES: Ten Entertainment, Emmerson chairs step down

Thu, 25th Mar 2021 15:57

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Thursday and not separately reported by Alliance News:

----------

Ten Entertainment Group PLC - Cranfield, England-based tenpin bowling operator - Nick Basing will step down as chair in September, after 6 years in the role and 12 with the company and its predecessor Essenden. Company has started the process of finding a replacement.

----------

Emmerson PLC - Khemisset potash project in northern Morocco - Mark Connelly retires as non-executive chair at general meeting, during which shareholders also approved Emmerson's move to AIM from the London Main Market, effective from Friday. Non-Executive Director James Kelly is promoted to independent non-executive chair.

----------

Ceres Power Holdings PLC - Horsham, West Sussex-based solid oxide fuel cell developer - Hires Tudor Brown as independent non-executive director, starting Thursday next week. Brown was among the founders of computer chip designer ARM Holdings PLC and served ARM as chief technology officer and chief operating officer. He is on the board of Hong Kong-listed personal computer and smart phone maker Lenovo Group Ltd.

----------

Atalaya Mining PLC - copper and silver mining in Spain - Jose Sierra will retire as an independent non-executive director on Wednesday next week, having served on the Atalaya board since 2011.

----------

Euromoney Institutional Investor PLC - London-based business media and events - Lorna Tilbian steps down as non-executive director, effective immediately, "to spend more time focusing on her other business interests".

----------

Biome Technologies PLC - Southampton, Hampshire-based biodegradable plastics and radio frequency systems - Hires Simon Herrick as non-executive director, joining immediately. Herrick is a non-executive director of London listings Ramsdens Holdings PLC and FireAngel Safety Technology Group PLC. As an executive, Herrick was chief financial officer for a number of companies, including department store chain Debenhams and Blancco Technology Group PLC. He will replace Michael Kayser as chair of the audit and remuneration committees when Kayser retires from the board at the Biome's annual general meeting on April 21.

----------

Avacta Group PLC - Wetherby, England-based developer of cancer immunotherapies - Mike Owen steps down as non-executive director, effective immediately, but remains chair of Avacta's scientific advisory board.

----------

Arrow Global Group PLC - European investor and alternative asset manager of loan portfolios - Appoints Davide Stecchi as managing director of Underwriting to lead the Arrow Capital Management underwriting team. Prior to joining Arrow, Stecchi spent 7 years at Hudson Advisors.

----------

Tirupati Graphite PLC - London-based graphite producer with operations in Madagascar and India - Strengthens its team across its three business units to support its growth. Appoints Biswal as head of the Tirupati Graphene & Mintech Research Centre. Names Sathpathy as an advisor to the company, specially focussed on application of graphene in aluminium manufacturing smelters and graphene aluminium composites development. Appoints Dash, who is also focused on graphene engineering science, to board.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
21 Mar 2024 13:10

Avacta reaches milestone in AVA6000 dose escalation

(Sharecast News) - Avacta Group announced a significant milestone in its phase 1a dose escalation study of AVA6000, its lead 'preCISION' drug, on Thursday.

Read more
21 Mar 2024 10:37

Avacta doses third patient in drug conjugate trial for tumour tissue

(Alliance News) - Avacta Group PLC on Thursday said it dosed the third patient in the first cohort of its phase 1a dose escalation study for its lead preCision drug AVA6000.

Read more
18 Mar 2024 14:31

IN BRIEF: Avacta shareholders give AGM go-ahead to issue new shares

Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - At annual general meeting on Monday, shareholders approved the resolution to issue 23.9 million placing shares and 10.9 million Rex offer share, both at 50 pence each. This raises gross proceeds of around GBP11.9 million and GBP5.4 million respectively. Combined with proceeds from an earlier firm placing and direct subscription, the shares for which were admitted to trading on March 4, Avacta has raised total gross proceeds of GBP31.1 million.

Read more
5 Mar 2024 17:09

EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
29 Feb 2024 12:18

Avacta increases placing size to GBP26 million thanks to strong demand

(Alliance News) - Avacta Group PLC on Thursday said it is increasing its placing to GBP25.7 million, "in light of the strong demand."

Read more
29 Feb 2024 10:27

AIM WINNERS & LOSERS: Beacon Energy and Avacta fall on fundraise

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
29 Feb 2024 08:27

Avacta tumbles after raising £25.7m in heavily discounted placing

(Sharecast News) - Healthcare therapeutics company Avacta tumbled on Thursday after a heavily discounted placing.

Read more
28 Feb 2024 20:31

TRADING UPDATES: Avacta plans fundraise to fund clinical development

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
19 Jan 2024 11:18

Avacta appoints new head of research and development

(Sharecast News) - Oncology drugs and diagnostics developer Avacta announced the appointment of Dr Christina Coughlin as its new head of research and development for the therapeutics division on Friday.

Read more
19 Jan 2024 09:11

IN BRIEF: Avacta says new head of R&D Coughlin brings "deep expertise"

Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - Appoints Christina Coughlin as head of research and development. Coughlin, who will take up the position on February 1, has served as a non-executive director of Avacta since March 2022 and was appointed consultant in interim in September 2023. She previously served as chief executive officer of Cytoimmune Therapeutics LLC, a clinical stage biotechnology company focused on novel cancer immunotherapy products. In the new role, Coughlin will oversee clinical and pre-clinical research and development activities for the company's therapeutics division, while retaining her position on as an executive director of Avacta. The company says that Coughlin has been "pivotal" in the development strategy for its AVA6000 tumour-targeted therapy.

Read more
19 Dec 2023 10:24

Avacta appoints new chief business officer

(Sharecast News) - Oncology drugs and diagnostics specialist Avacta Group announced the appointment of Dr Simon Bennett as the chief business officer of its therapeutics division on Tuesday.

Read more
19 Dec 2023 09:57

IN BRIEF: Avacta taps biopharma veteran as Therapeutics business chief

Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - Hires Simon Bennett as chief business officer of Therapeutics division. Says Bennett has over 26 years of commercial experience in the biopharma industry and has "worked with" various large and mid-sized companies like Bristol-Myers Squibb Co and Menarini Group.

Read more
13 Dec 2023 11:49

Avacta says study shows cancer treatment AVA6000 working as planned

(Alliance News) - Avacta Group PLC on Wednesday celebrated strong results from its latest cancer-targeting study, which showed the release of a chemotherapy to the tumour as intended.

Read more
13 Dec 2023 07:46

Avacta hails "encouraging" clinical data from cancer-targeting study

(Sharecast News) - Oncology drugs group Avacta has announced positive results from its lead pre|CISION programme, AVA6000, which it says has the potential to be "truly remarkable".

Read more
28 Sep 2023 11:08

IN BRIEF: Avacta loss widens on cost rise but clinical tests positive

Avacta Group PLC - Wetherby, England-based life sciences company that develops targeted oncology drugs and diagnostics - Pretax loss widens to GBP12.8 million in the six months that ended June 30 from GBP9.7 million a year before. Revenue doubles to GBP11.9 million from GBP5.5 million, but selling, general and administrative expenses near double as well, to GBP8.6 million from GBP4.7 million. Research costs are steady at GBP6.0 million. Has GBP26.0 million cash, up from GBP17.0 million a year before, though down from GBP41.8 million on December 31. Highlights success of AVA6000, a chemotherapy drug for cancer patients, in a Phase 1a clinical study. Avacta aims to complete a dose escalation safety study and provide results during the fourth quarter.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.